Tg Therapeutics, Inc. (NASDAQ:TGTX)
| Market Cap | $9.57B+98.3% |
| Revenue (ttm) | $897.76M+68.8% |
| Net Income | $106.06M-76.3% |
| EPS | $0.66-76.3% |
| Shares Out | 151.15M |
| PE Ratio | 85.03 |
| Forward PE | 22.85 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,087,261 |
| Open | $64.32 |
| Previous Close | $64.88 |
| Day's Range | $63.12 - $65.64 |
| 52-Week Range | $26.76 - $68.03 |
| Beta | 1.81 |
| Analysts | Buy |
| Price Target | $80.50(+27.09%) |
| Earnings Date | Feb 25, 2027 |
About TGTX
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating TGTX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 25, 2027Earnings report
$TGTX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TGTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TGTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TGTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TGTX Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New TGTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TGTX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TGTX
| IJRiShares Core S&P Small-Cap ETF | $554.30M |
| IWMiShares Russell 2000 ETF | $247.21M |
| VTIVanguard Morningstar Total Stock Market ETF | $212.43M |
| VBVanguard Morningstar Small-Cap ETF | $188.96M |
| XBIState Street SPDR S&P Biotech ETF | $179.80M |
| FBTFirst Trust NYSE Arca Biotechnology Index Fund | $115.77M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from TGTX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings and revenue beat, raised 2026 guidance, Deloitte Fast 500 ranking, and positive analyst coverage outweigh valuation concerns.
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 15Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| PSCH | Invesco S&P SmallCap Health Care ETF | 4.91% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 3.80% |
| PBE | Invesco Biotechnology & Genome ETF | 3.18% |
| GRPZ | Invesco S&P SmallCap 600 GARP ETF | 2.20% |
| XBI | State Street SPDR S&P Biotech ETF | 1.77% |
| BBP | Virtus Biotech ETF | 1.71% |
| XSHQ | Invesco S&P SmallCap Quality ETF | 1.62% |
| RZG | Invesco S&P SmallCap 600 Revenue ETF | 1.62% |
| SAWS | AAM Sawgrass U.S. Small Cap Quality Growth ETF | 1.52% |
| HYP | Golden Eagle Dynamic Hypergrowth ETF | 1.24% |
| JSML | Janus Henderson Small Cap Growth Alpha ETF | 1.15% |
| CTAG | Calamos Timpani Active SMID Growth ETF | 1.14% |
Weight is the stock’s share of each fund’s holdings.
